Submitted by Anonymous (not verified) on 24 August 2026 - 10:27
Orphan designation: rozanolixizumab Treatment of myelin oligodendrocyte glycoprotein antibody-associated disease, 28/07/2026 Positive
Source:
Orphan designation: rozanolixizumab Treatment of myelin oligodendrocyte glycoprotein antibody-associated disease, 28/07/2026 Positive